South Korea's DAAN Biotherapeutics has entered an exclusive deal with LigaChem Biosciences to develop a novel tumor-targeting ...

Antengene (HK: 6996) has announced that its multiple myeloma treatment, Xpovio (selinexor), will be included in Taiwan’s ...

Global private equity firms Blackstone, Brookfield Corporation and Warburg Pincus are in talks to acquire a majority stake in ...

The Food and Drug Administration (FDA) has approved a New Drug Application (NDA) from Swiss pharma giant Roche’s subsidiary ...

In its annual results statement, Galapagos chief financial officer Thad Huston said the firm is moving ahead with a planned ...

Danish biopharma giant Novo Nordisk (NOV: N) is breaking new ground with its GLP-1 agonist semaglutide, as a small mid-stage ...

The US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Adcetris ...

Australian radiopharma company Telix Pharmaceuticals (ASX: TLX) has gained approval from the UK Medicines and Healthcare ...

The European Commission (EC) has approved catumaxomab, making it the only approved drug therapy for malignant ascites (MA) for patients living with this debilitating condition across Europe.

IN8bio has announced encouraging new clinical data from its ongoing Phase I trial of INB-100, an allogeneic gamma-delta T ...

An Expert View from Nick Petschek, EMEA managing director at global change management firm Kotter International.

Shares in AnaptysBio, a San Diego-based biotech focused on delivering innovative immunology therapeutics, was trading 19% ...